Order Article Reprints

López González A, Del Barco Berrón S, Grau I, Galan M, Castelo Fernández B, Cortés A, Sánchez Rovira P, Martinez-Bueno A, Gonzalez X, García A, et al. Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers. 2022; 14(23):5880. https://doi.org/10.3390/cancers14235880

López González, Ana, Sonia Del Barco Berrón, Isabel Grau, Maria Galan, Beatriz Castelo Fernández, Alfonso Cortés, Pedro Sánchez Rovira, Alejandro Martinez-Bueno, Xavier Gonzalez, Almudena García, and et al. 2022. "Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study" Cancers 14, no. 23: 5880. https://doi.org/10.3390/cancers14235880

López González, A., Del Barco Berrón, S., Grau, I., Galan, M., Castelo Fernández, B., Cortés, A., Sánchez Rovira, P., Martinez-Bueno, A., Gonzalez, X., García, A., Gener, P., Mina, L., Alcalá-López, D., Sampayo, M., Cortés, J., Pérez-Garcia, J. M., Llombart-Cussac, A., & López-Miranda, E. (2022). Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers, 14(23), 5880. https://doi.org/10.3390/cancers14235880